Background. Most hepatitis delta virus (HDV) prevalence estimates from the United States are 110 years old, and HDV has shown significant temporal variation in other populations. HDV-hepatitis B virus (HBV) dual infection progresses rapidly, has more complications, and has a different treatment regimen than HBV infection alone. Accurate estimates of prevalence and risk factors are important to help clinicians decide who to screen.
rapid progression and a higher rate of complications, such as cirrhosis, end-stage liver disease, and hepatocellular carcinoma, than in HBV infection alone [4] [5] [6] [7] [8] [9] [10] . A recent multicenter study found that patients dually infected with HDV and HBV had 3 times the risk of hepatocellular carcinoma and twice the rate of death due to cirrhosis compared with patients with HBV alone. A natural history study of viral hepatitis-related cirrhosis found that the median time to cirrhosis was 2 years [5, 6] ; in contrast, hepatitis C (HCV)-related cirrhosis has a median onset time of ∼20 years [11] .
HDV is found throughout the world, but its prevalence, incidence, clinical features, and epidemiological characteristics vary by geographic region [12] . HDV is endemic in many regions where there is a high prevalence of HBV, ranging from 70% among chronic HBV carriers in the Amazon basin to 20% in Africa to !1% in North America [12] [13] [14] [15] [16] [17] .
While the overall prevalence of HDV in the United States is very low, it is elevated among populations at higher risk of HBV and other bloodborne infections [12, 13, [16] [17] [18] . However, even in subpopulations with high levels of HBV, considerable variation in HDV prevalence has been reported. Nath et al [12] found that the prevalence of HDV among blood donors in the United States differed significantly by region, ranging from 1.4% among chronic HBV carriers in the Southeast to 12.1% among chronic carriers in the Pacific region. Other studies have found rates varying from as low as 2% in hepatitis B surface antigen (HBsAg)-positive homosexual men to as high as 21% in female prostitutes [17, 18] . It has been 110 years since HDV prevalence was systematically measured in the United States. Furthermore, there is limited information available from populations in the United States to elucidate what places an individual at risk for contracting HDV.
Injection drug users have higher rates of HBV than the general population, making them particularly susceptible to HDV infection [19] . Chaotic lifestyles, limited health care access, and fear of retribution for drug use make injection drug users difficult for researchers to study, and few studies have measured the burden of HDV among injection drug users in the United States. The goals of our study were (1) to characterize current HDV prevalence and changes in prevalence over time in the Baltimore injection drug user population, (2) to identify correlates of HDV exposure and viremia, and (3) to characterize HBV, HDV, and HCV viral dynamics among those with HDV exposure.
METHODS

Study Population
The AIDS Linked to the Intravenous Experience (ALIVE) cohort is a longitudinal cohort study of 3360 current and former injection drug users (both human immunodeficiency virus [HIV]-positive and HIV-negative participants) in Baltimore, Maryland, that has been operational for 120 years. Participants are seen at semiannual visits that include HIV testing and collection of behavioral data, clinical data, and biological samples. Details of the ALIVE cohort have been provided elsewhere [19] . This study was approved by the Johns Hopkins institutional review board, and all participants gave informed consent.
Study Design
We used a cross-sectional design and stratified random sampling scheme to estimate the prevalence of exposure to HDV among current and former injection drug users in Baltimore during 2 time periods: 1988-1989 (baseline) and 2005-2006 (recent) . Because the majority of the participants in the 2005-2006 cohort were recruited after 1994, this study is best described as a cross-sectional prevalence study of injection drug users in Baltimore at 2 time points rather than a longitudinal study of the same patients over time. ALIVE participants were stratified into 3 categories according to their HBV serologic test results: (1) HBsAg positive for 16 months (chronically infected) [20] ; (2) hepatitis B core antibody (anti-HBc) positive, hepatitis B surface antibody (anti-HBs) positive, and HBsAg negative (prior infection and immunity); and (3) anti-HBc positive only (likely previously exposed) [21] . Those who were anti-HBs positive only were assumed to have been vaccinated for HBV and excluded from analysis (76 participants, 2.9% of the 1988-1989 cohort; 62 participants, 5.0% of the 2005-2006 cohort). A random sample of patients was chosen from each HBV category at each time point by using a random-number generator. Stored serum samples collected during the same visits at which HBV testing was performed were evaluated for hepatitis delta antibody (HDAb).
Laboratory Methods
Antibody testing. Testing for anti-HBc and anti-HBs was performed using the Abbott Corzyme immunoassay (Abbott Laboratories). The Abbott Auszyme immunoassay was used to detect HBsAg in the baseline samples (Abbott Laboratories), and the DiaSorin HBsAg assay was used for the recent samples (DiaSorin). A sensitivity study of commercial HBsAg assays found DiaSorin and Abbott to be comparable [22] . All assays were performed according to the manufacturer's protocols. Reactive samples were confirmed through repeat testing; there were no discordant results. The baseline samples were tested for presence of HDAb using radioactive immunoassay (RIA), the standard assay available in 1994 when the testing was performed. The recent samples were tested using an enzyme-linked immunoassay (ELISA) for the determination of antibodies to hepatitis delta virus in serum samples (Diagnostic Bioprobes Srl). Validation studies of RIA and ELISA for detection of HDAb have shown that the ELISA has 100% specificity, but only 92% sensitivity when compared with RIA. The reduced sensitivity generally occurs in patients with no or low-level viral replication who have lower titers of antibody, as the RIA has a lower minimum limit of detection than the ELISA [23, 24] . To account for the use of different testing methods, we report prevalence results both unadjusted and adjusted for the difference in sensitivity between the tests. 160 years), sex, race (categorized as white non-Hispanic, black, Native American, or other), HIV serostatus, hepatitis C antibody (HCVAb) status, HCV RNA status (detectable HCV RNA vs no detectable HCV RNA), serum aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, serum albumin level, and visit to an emergency room in the 6 months prior to the study date (yes or no) were compared between those who had no evidence of exposure to HDV (HDAb negative) and those who had been exposed (HDAb positive). The analysis was repeated comparing those who were HDV exposed but not viremic (HDAb positive but HDV RNA negative) to those who were viremic (HDV RNA positive). HBV and HCV load values were log transformed and compared between (1) HDV RNA positive (viremic) and HDV RNA negative, HDAb positive (exposed but not viremic) and (2) exposed but not viremic and HDAb negative (not exposed). Categorical variables were compared using 2-sided x 2 tests; continuous variables were compared using 2-sided t tests.
To examine associations between drug use and sexual behaviors and HDV, we calculated the relative risk [25] of HDV exposure (HDAb-positive test result) among those participants who reported each behavior in the 6 months prior to visit date compared with that among participants who did not. We report 95% confidence intervals and P values for each relative risk value. These were performed on the 2005-2006 samples only, because more complete behavioral data were available for this cohort. Analyses examining sexual behavior were stratified by current injection drug use (yes or no). All data were analyzed using STATA statistical software, version 11.0 (Stata Corp). Figure 1 shows the number of eligible participants sampled at each time point. A total of 243 participants who were HBV positive at baseline (between 1988 and 1989) were randomly selected. Of these, 194 (79.8%) had serum available in the repository at the appropriate visit, which was tested for HDV. In the second cohort, 258 of 259 randomly selected HBVpositive participants had serum available for HDV testing. To evaluate whether the samples not available in the repository were missing at random, the demographic characteristics of participants with serum available were compared with those who did not have serum available. Within HBV strata, there were no statistically significant differences in the demographic or clinical characteristics between participants tested and participants who did not have serum available, indicating the serum samplers were missing at random (data not shown). Table 1 compares the demographic characteristics of the 2 cohorts from each time period. Participants from the baseline cohort were more likely to be younger, male, married, have an income, and be HIV-negative than participants from the current cohorts. The proportion of black participants and HCVAbpositive participants was similar between the 2 time periods.
Missing Data
RESULTS
Prevalence of HDV Exposure over Time
HDV prevalence in 1988-1989 was 11% in participants who were previously exposed to HBV and 29% in those who were chronically infected with HBV (Table 2 ). HDV prevalence de- 
Behavioral Correlates of HDV Exposure
In an analysis of drug use behaviors and HDV infection, visiting a "shooting gallery" (a location where people gather to inject NOTE. Demographic and clinical characteristics comparing those participants with no HDV exposure (HDAb negative) to those with HDV exposure (HDAb positive) and those participants with HDV exposure but no viremia (HDAb positive but RNA negative) to those with HDV viremia (HDV RNA positive), ALT, alanine aminotransferase; AST, aspartate aminotransferase; ED, emergency department; HDAb, hepatitis delta antibody, as measured by ELISA; HIV, human immunodeficiency virus; NA, not applicable; RNA, detectable hepatitis delta RNA in qualitative assay, IU/mL. a Other racial and ethnic categories measured included black-Hispanic, white-Hispanic, and Asian; however, no participants in this cohort identified in those categories. b Percentage of participants who had у1 emergency room visit during the 6 months prior to their study date.
illegal drugs) was the only statistically significant correlate of HDV infection ( 
Demographic and Clinical Correlates of HDV Exposure
Compared to those with no exposure to HDV (HDAb negative), a lower proportion of HDV-exposed (HDAb-positive) participants were black (75% vs 89.6%; ), and a higher P p .03 proportion identified as white, non-Hispanic, or other. Those with HDV exposure were more likely to be HIV positive (56% vs 35.6%;
). There were no statistically significant dif-P p .046 ferences in age, sex, HCVAb status, serum AST, ALT, or albumin level, or likelihood of an emergency room visit between those who were HDV exposed and those who were not exposed (Table 4).
Demographic and Clinical Correlates of HDV Viremia
Among the 25 participants who were HDAb positive, 8 (32%) had detectable HDV RNA. Those with detectable HDV viremia were on average younger (mean age, 41.1 vs 49.9 years; P p ), with the majority between 18 and 45 years old. HDV-.004 viremic participants had significantly higher AST levels (125.7 vs 49.6 U/L for those without viremia;
), ALT levels P p .03 (132.3 vs 31.1 U/L; ), and lower albumin levels (3.6 P p .009 vs 4.2 g/DL;
). They were also significantly more likely P p .03 to report at least 1 visit to the emergency room in the 6 months prior to study date (62.5% of HDV-viremic participants vs 18.8% of HDV-nonviremic participants;
). All HDV-P p .03 viremic participants (100%) were HIV positive, compared with only 35.3% of nonviremic participants ( ). Only 37.5% P p .002 of those who were viremic for HDV had detectable HCV-RNA, compared with 76.5% of those who were nonviremic; however, this difference was not statistically significant. None of the HDV-viremic participants were female, compared with 31.3% of those who were nonviremic ( ). P p .1
Viral Load Measures
Comparison of HBV and HCV loads between HDV-viremic and nonviremic participants. Those who were viremic for HDV had a mean HBV DNA level of 232,229,000 IU/mL compared with 700 IU/mL for those who were not viremic (P ! ; Table 5 ). When the analysis was restricted to those who .001 were HBsAg positive only, a significant difference between the 2 groups remained ( ). HCV load was slightly higher in P p .02 those who were viremic for HDV (150,288,000 vs 3,246,000 IU/mL), but that difference was not statistically significant.
Comparison of HBV and HCV loads between HDAb-positive, RNA-negative, and HDAb-negative participants. Participants who were exposed to HDV (HDAb positive) but not viremic had significantly lower levels of HBV DNA than those with no exposure (700 vs 245,887,000 IU/mL, ; Table 5 ). This P p .007 difference persisted even when the analysis was restricted to those who were HBsAg positive (1300 vs 312,087,000 IU/mL; ). HCV load was slightly lower in the HDV-exposed, P p .01 nonviremic group (3,246,000 vs 38,869,000 IU/mL among those not exposed to HDV), but the difference was not statistically significant.
DISCUSSION
Our study found a higher prevalence of HDV among injection drug users with chronic HBV infection than had previously been reported in the United States, with 50% infected in [2005] [2006] . The majority of prior studies were performed in healthcare settings, which may lead to an underestimate of HDV prevalence by excluding individuals with limited access to health care, given that such individuals may be at increased risk of acquiring HDV. The most recent estimate of HDV infection among HBsAg-positive individuals comes from NHA-NES 2003 -2004 , in which participants who were HBsAg positive and anti-HBc positive were tested for HDAb. Only 1 (3.6%) of 28 were HDAb positive [26] , suggesting that the higher HDV prevalence may be concentrated in the injection drug user population.
Visiting a "shooting gallery" emerged as the most important behavioral risk factor for HDV infection. Previous studies suggest that HDV is more efficiently spread parenterally than sexually [27] . Our study corroborates these findings. However, there was evidence to suggest that high-risk sexual behavior might be important among infrequent or non-injection drug users. More studies are needed to better understand the role of sexual transmission in HDV infection. However, our data are troubling because sexual transmission could facilitate the spread of HDV from injection drug users to their sexual partners and subsequently to the general population.
Participants who were HDV viremic had significantly higher levels of AST and ALT, lower levels of albumin, and an increased likelihood of a recent emergency room visit. These differences may be partially explained by HIV, which was present in all HDV-viremic participants compared with only 31.1% of nonviremic participants. Progression to chronic HBV infection after acute infection is largely related to the immune status of the host. HIV infection is associated with greater likelihood of progression to HBV chronicity [28] , and this may be true for HDV as well. Unfortunately, the cross-sectional nature of our study does not allow for determination of whether HIV infection predated the HBV-HDV infection.
We found that participants who were exposed to HDV but were not viremic had significantly lower HBV load levels compared with both HDV-negative patients and HDV-viremic patients. It is possible that this group is mostly composed of participants who were coinfected with HDV (they acquired both HDV and HBV at the same time, an event associated with clearance of both viruses the vast majority of the time) [29] . The lowered HCV load among HDV-viremic participants corroborates previous findings that HCV replication is inhibited in the presence of HDV [30, 31] . However, HCV load was not uniformly lowered among HDV-viremic participants; in fact, some had very high viral loads, as such careful monitoring of hepatitis viral levels is necessary in patients with HDV.
One limitation of our study was the use of different HDAb testing methods at the 2 testing points. On the basis of the results of a previous study that compared HDAb RIA with ELISA in 1000 participants, we were able to adjust for the differences in sensitivity between the assays. The authors of the validation study noted that the discrepancy was predominately seen in patients with little or no active viral replication [24] . This is most likely to affect patients who have already cleared both viruses, because antibody titers wane over time and may eventually become undetectable. In such patients, antibody detection will depend on the sensitivity of the assay used. Patients with persistent HDV infection will maintain high levels of anti-HDV antibodies because of chronic antigenic stimulation [29] . In this scenario, the patient will test positive for anti-HDV using both methods. Therefore, we believe that the increase among chronic carriers is likely to be accurate. In patients who were previously exposed to HBV, some individuals whose test results were negative by ELISA may have had positive test results by RIA. This would suggest that, if incorrect, the observed increase in HDAb prevalence among individuals who had been previously exposed to HBV may actually be an underestimate. Furthermore, the 8% difference in sensitivity observed between ELISA and RIA was seen in patients who were all HBsAg positive. This difference may be greater at lower antibody titers likely to be seen in HBsAg-negative patients, meaning that even the adjusted ELISA estimate of the participants previously exposed to HBV may be an underestimate of the true HDV prevalence. An additional limitation of our study is the use of behavioral data measured at time of testing rather than at time of exposure. We cannot exclude the possibility that infection with HDV or HBV might change an individual's behavior, thus introducing a systematic bias into our results. Misclassification of this type would bias results towards the null; as such, our behavioral risk factor analysis should be interpreted with this in mind.
Our findings underscore the importance of HBV vaccination, because it can prevent both HBV and HDV infections. Rates of HBV vaccination as measured by serologic testing (HBsAb positive, cAb negative, and sAg negative) were very low (2.9% in 1988-1989 and 5.0% in [2005] [2006] . Accordingly, efforts should be made to expand HBV vaccination coverage to atrisk populations, such as injection drug users. It is possible that the low prevalence of patients with serologic test results positive for HBsAb only is not entirely explained by decreased access to the vaccine in this population, but might also reflect decreased efficacy due to high rates of HIV infection [32] . It is also possible that HBV infection predated vaccination for many in this cohort. Additional research is needed to determine true levels of access and efficacy of the HBV vaccine in injection drug user populations.
Increasing prevalence of HDV among injection drug users has potentially important clinical implications. HDV-HBV coinfection is generally more severe than HBV monoinfection in patients with acute infection, with a higher risk of fulminant hepatitis [29, 33] . In patients with superinfection and chronic infection, HDV has been shown to suppress HBV replication, potentially confounding clinicians because significant liver disease often occurs despite low or undetectable levels of HBV DNA [34] . This can lead to delayed diagnosis, which is particularly troubling, given the more aggressive nature of HBV-HDV chronic infection [4] [5] [6] . In addition, oral nucleoside and/or nucleotide analog therapy, standard treatment for HBV infection, is ineffective in the presence of HDV, leaving high-dose prolonged interferon therapy as the only option [35] . Our data suggest that all patients infected with HBV with a history of past or present injection drug use should be screened for HDV. Careful screening combined with additional studies to better understand this change in epidemiological profile should be a priority to reduce the significant morbidity associated with HDV infection and to prevent the prevalence from rising further.
